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Medical Supervision
History, physical examination, and blood tests were perf@rmed prior to the initiation ofAP therapy; every six weeks, and whenever clinically indicated. Patients were screened for an infection or lung disease every time they came for their treatment. Posteroanterior and lateral chest roentgenograms and Dco were performed prior to administering the pentamidine, and whenever clinically indicated. When PCP was suspected, evaluation always included a chest roentgenogram, bronchoscop@; and bronchoalveolar lavage. Con firmed PCP was treated appropriately after which most patients resumed their AP therap):
Pulmonary Function Tests
Spirometry and Dc were performed on a system (Tektronix 4051 system with a Med-Science wedge). Pulmonary function tests were performed on average 12Â± 3 days prior to AP therapy in all patients and 12Â± 5 days prior to AP therapy in the patients who developed pnetimothoraces.
Correction of Dco for hemoglobin was performed using the formula proposed by Cotes'7 where adjtLsted DL = observed DL ([10.22Â± lIb] I 1.7 lIb).
Statistical Analysis
Pneumocystis carinii pneumonia incidence curve was generated according to the Kaplan-Meier'@ method. Three groups of patients were analyzed; (1) those who did not develop PCP or pneumothorax; (2) those who developed PCP without pneumothorax; and (3) those who developed pneumothorax.
Comparisons between groups were either performed l)% Student t tests when groups 1 and 2 were combined and compared with group 3 or by analysis of variance for all three groups. A p<O.05 was considered as significant. Results are presented as mean Â± standard error ofthe mean.
RESULTS
Aerosolized pentamidine was administered as sec ondary prophylaxis for PCP to 48 patients (46 men and two women); most were homosexuals or bisexuals Chest tubes were inserted in all patients on the side oftheir pneumothoraces and removed only when the air leaks ceased. The course was similar in the four patients with the longest survival. Pneumo thoraces persisted on at least one side despite chest tube drainage. Two patients were treated with surgical pleurodesis on one side. All patients suffered from anorexia with progressive cachexia. Palliative measures were adopted with the consent of the patients. All patients died with at least one chest tube in place.
Except for the patient who died 14 days after hospital admission, none of the deaths seemed related to PCP (dehydration, cachexia, bacterialpneumonia, septi cemia).
Several factors may have influenced the appearance of pneumothorax in these patients. However, patients with pneumothorax did not seem to be more immu nosuppressed since they did not have more prior episodes of PCP before starting AP therapy @ordid they suffer from more infections during the study period (Table 3) Patients with pneumothorax complained of symptoms for 6.8 Â± 3.3 days prior to presentation to the hospital, whereas patients with PCP without pneumothorax were symptomatic for 18.6 Â± 5 days prior to presenting to the hospital.
When pulmonary function tests prior to AP therapy were assessed, all spirometric values were normal except uncorrected and corrected Dco, which were low in all three groups (Table 4) . Dco was significantly higher in the patients who went on to develop PCP without pneumothorax when compared with the two other groups. When the Dco of the patients with pneumothorax was compared with that of all other patients, uncorrected Dco was significantly lower (p = 0.024) and corrected Dco tended to be signifi cantly lower (p = 0.053).
DISCUSSION

Pneuniocystis carinii is the most common cause of pneumonia in patients with AIDS.'2 This pneumonia
has an incidence of up to 80 percent in these patients The incidence of pneumothorax in PCP seems to be increasing in frequency. Goodman et alh2 reported seven cases of pneumothorax in 1986 when a review published in 1984@ had reported none.
When the occurrence of pneumothorax in AIDS patients was studied prospectively,@ the overall mci dence was 2 percent with an increased relative risk in those having suffered from one or several PCPs and those receiving AP therapy. Several reports have also suggested that AIDS patients receiving AP may be at increased risk for pneumothorax.@ The exact mci dence ofpneumothorax in these patients is difficult to assess in view of the increased mortality and short length offolbow-up in the published studies. However, the incidence varies between 0 percentas and 6.3 percent.@ In our patients, the incidence of pneumo thorax was 10.4 percent. The differences in incidence do not seem to be related to a technical factor since we used the same protocol for aerosolization as the Toronto Pentamidine Study Group.@ The increased incidence ofpneumothorax also does not seem related to a problem of administration of pentamidmne. In deed, if a decrease in recurrence of PCP is a sign of proper administration of the medication, recurrence at one year in our study patients was comparable to
that reported by Leoung et a15(with the Respigard II). It thus seems that the AP was being deposited into
the lungs and preventing recurrences ofPCP The high rate ofpneumothoraces may be due to a longer follow up in our patients or more underlying lung disease prior to AP therapy (decreased Dco).
Several factors could explain the occurrence of a relatively high incidence of pneumothorax in AIDS patients treated with AP Aerosolized pentamidine is deposited in higher concentrations in the proximal airways and is less well-distributed to the periphery of the lungs.@ A slowly spreading, peripheral, necro tizing pneumonitis could extend to the pleural surface and cause a bronchopleural fistula with resultant pneumothorax as well as clinically apparent PCP as described in some â€˜Â°â€ẫ€@â€ẫ€˜@ Another reason could be that patients with a history of PCP are at increased risk for a recurrence.4 Since PCP is associated with an increased risk of pneumothorax, recurrence of PCP in and a high recurrence rate during the first year.4
Aerosolized pentamidine is effective for the primary and secondary prophylaxis of PCP in AIDS patients.4'5
As a prophylactic regimen, AP would be expected to increase the length of survival of patients with AIDS. However, this has yet to be shown, possibly because of the short length of follow-up in the published studies.4'5 We have presented the survival and respi ratory complications of 48 patients receiving AP as secondary prophylaxis for PCP During a study period of an average of 412 days, five patients developed pneumothoraces and all died a mean of 66 days after their first pneumothorax. These deaths represented 42 percent of all patient deaths and underline the importance of pneumothoraces as a negative effect on the survival of our AIDS patients. These results have an even more important impact since the occurrence ofPCP without a pneumothorax did not affect survival.
The clinical course seemed the same in most of the five patients who developed pneumothoraces. Unre solving air leaks were accompanied by anorexia and wasting until both patients and their physicians opted for conservative measures. Our results suggest that improvement in survival in these patients would thus be obtained by the prevention and not the treatment of their pneumothoraces.
Bullous lesions and pneumothoraces
have been reported in the setting of acute PCP or as a late sequelae of PCP.@5@ Ivady et al2i described five radiologic stages of PCP in infants. In the third stage, the peripheral parts of the lung were described as â€oeemphysematous.â€•In the fifth stage, the authors described â€oeemphysematous blebsâ€•that can result in pneumothorax from rupture. In AIDS patients with PCP, cystic lesions have been reported on the chest roentgenogram in 7 and 10 percent of patients, re spectively.1@'@ When computed tomographic (CT) scans of the lungs were performed in 55 AIDS patients,9 bullous damage located predominantly in the apical and cortical areas of the lungs was found in 42 percent. However, only 70 percent of the patients with bullous lesions had suffered from one or more lung infection, which suggests that bullous disease of the lungs may not only be related to lung infection. 
It is interestingthat the only significantdifference
between the patients who developed pneumothorax and those who did not was an abnormal uncorrected single breath diffusion capacity prior to receiving AP.
Part ofthis difference was explained by anemia, which is a possible sign of more severe disease in these patients. However, the Dco prior to AP therapy seemed lower in the patients who developed pneu mothorax even after correction for the anemia (p = 0.053). We believe this difference to be significant in view of the small number of patients5 who developed pneumothorax. The small size of this group may also have masked significant differences in other baseline characteristics. The patients who presented with pneu mothorax seemed to have an underlying lung disease that affected diffusion but not the lung volumes or the chest roentgenogram prior to receiving AP. Postinfec tious pulmonary fibrosis could have been present in these lungs but it would be difficult to explain the normal chest roentgenograms in all the patients who had an important decrease in diffusion. Recurring PCP is a possibility since AP therapy was started relatively late after the last PCP (155 days) but the amount of AP administered is prophylactic and not therapeutic.
It is thus difficult to explain the latency of 201 days between the administration of AP and pneumothorax and the same LDH levels in all groups. â€oeEmphysematousâ€•cystic lung disease is a more likely possibility in view of the increased incidence of bulbous lung disease described in AIDS 1)atients, especially after PCP.9 Progression of these abnormal lung lesions either through the recurrence of PCP, another pulmonary infection, an im mune mechanism, Or a toxic effect of pentainidine could have led to the pneumothoraces presented . Howe@er, the Dco has been shown to increase in patients receiving AP for secondary prophylaxis of PCP.26 A toxic effect of AP would thus seem a less likely explanation.
In conclusion, our results show that pnetiin@tl@@r@x is a significant complication in patients receiving AP for secondary prophylaxis of PCP and is associated with a high mortality. We do not know whether AP increases the incidence of Pnetlm@th0rax. However, 
